Compound Detail

CHEMBL4650485

PIRTOBRUTINIB

💊 Approved Drug

Enter ChEMBL ID:

Free Research Context This compound will appear in recent viewed items on the research home for this browser.

Research home View demo workspace

💊 Approved Drug

COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn([C@@H](C)C(F)(F)F)c(N)c2C(N)=O)cc1

ChEMBL ↗ Properties Compare Identifier

Basic Information

ChEMBL ID	CHEMBL4650485
Name	PIRTOBRUTINIB
Phase	Approved
Structure Type	MOL
InChI Key	FWZAWAUZXYCBKZ-NSHDSACASA-N
Therapeutic	✓ Yes

Known Names

Jaypirca Loxo-305 LY-3527727 LY3527727 Pirtobrutinib RXC-005

Targets

Activities

Assay Types

PK Parameters

Publications

Known Names

Indications

Mechanisms

Molecular Properties

479.4

MW (Da)

3.43

ALogP

HBA

HBD

125.3

PSA (Å²)

0.45

QED

Ro5 Violations

Rot. Bonds

Drug Information

Molecule Type	Small molecule
First Approval	2023
Availability	Prescription
Chirality	Single Enantiomer

Routes of Administration

Oral

USAN Stem	-tinib
USAN Year	2021

Extended Properties

Molecular Formula	C22H21F4N5O3
MW	479.43
Aromatic Rings	3
Heavy Atoms	34
NP-Likeness	-1.39

Mechanism of Action

Mechanism	Action Type	Target	Direct	Efficacy
Tyrosine-protein kinase BTK inhibitor	INHIBITOR	Tyrosine-protein kinase BTK	✓	✓

Indications

Lymphoma, Mantle-Cell Neoplasms Leukemia, Lymphocytic, Chronic, B-Cell Leukemia Lymphoma, B-Cell, Marginal Zone Multiple Sclerosis Waldenstrom Macroglobulinemia Renal Insufficiency

ATC Classification

L01EL05

pirtobrutinib

Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Level 2: ANTINEOPLASTIC AGENTS

Literature References

PubMed	DOI	Target Context	# Activities
34839996	10.1016/j.ejmech.2021.114009	Tyrosine-protein kinase BTK	2

Data from ChEMBL 36 via Core Engine